Press Releases InspireMD, Inc.

Equities

NSPR

US45779A8466

Delayed Nasdaq Other stock markets 09:59:24 15/05/2024 pm IST			5-day change	1st Jan Change
2.256 ^USD	-5.29%		+6.92%	-19.71%

14/05	Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	MT
06/03	Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InspireMD : Reports First Quarter 2024 Financial Results and Provides Business Update	14/05	PU
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th	07/05	AQ
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	AQ
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	26/03	AQ
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	06/03	AQ
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	28/02	AQ
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	12/02	AQ
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	31/01	AQ
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	03/01	AQ
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System	20/12	AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27/11	AQ
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update	06/11	AQ
InspireMD to Participate in Upcoming November Investor Conferences	02/11	AQ
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23	01/11	AQ
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th - InspireMD	31/23/31	AQ
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th	30/23/30	AQ
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients	12/23/12	AQ
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives	03/23/03	AQ
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23	31/23/31	AQ
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update - InspireMD	09/23/09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases InspireMD, Inc.

Equities

NSPR

US45779A8466

Press Releases

Filters